Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Expenses (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Operating Expenses for 4 consecutive years, with $81.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 14.14% to $81.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285.9 million through Dec 2025, down 17.94% year-over-year, with the annual reading at $285.9 million for FY2025, 17.94% down from the prior year.
  • Operating Expenses for Q4 2025 was $81.2 million at Day One Biopharmaceuticals, up from $64.0 million in the prior quarter.
  • The five-year high for Operating Expenses was $123.0 million in Q2 2024, with the low at $27.7 million in Q1 2022.
  • Average Operating Expenses over 4 years is $61.7 million, with a median of $61.8 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 149.72% in 2024, then tumbled 44.0% in 2025.
  • Over 4 years, Operating Expenses stood at $42.7 million in 2022, then soared by 39.24% to $59.5 million in 2023, then skyrocketed by 58.85% to $94.5 million in 2024, then decreased by 14.14% to $81.2 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $81.2 million, $64.0 million, and $68.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.